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Abstract
Background:  Malaria is the third most prevalent cause of infectious disease in the world.
Resistance of the parasite to classical drugs makes the discovery of new and effective drugs more
urgent. The oxidized derivative of hydroxy-cis terpenone (OHCT) is a synthetic molecule that is
not toxic to cultured human liver cells at concentrations as high as 60 μM and inhibits activity of
cytochrome P450s that metabolize many drugs.
Methods:  OHCT activity against chloroquine-sensitive and -resistant strains of Plasmodium
falciparum, and a P. falciparum clone that is partially resistant to artemisinin was assayed in vitro.
Results: OHCT at nanomolar concentrations was effective against all intraerythrocytic stages of
P. falciparum and exhibited activity in vitro against both chloroquine-sensitive and -resistant strains
of P. falciparum as well as a P. falciparum clone that is partially resistant to artemisinin. Moreover,
OHCT exhibited potent activity against gametocytes, the form that is transmitted by mosquitoes
and essential for the spread of malaria.
Conclusion: OHCT displays strong growth inhibitory activity against all stages of P. falciparum and
no evidence of toxicity to human cells in culture. It is easily synthesized and has the potential for
inhibiting metabolism of drugs used in combination therapies.
Background
Anti-malarial drug resistance is the major challenge to
reducing mortality caused by Plasmodium falciparum infec-
tion. Parasite resistance has caused some of the least
expensive, traditional anti-malarial drugs to be ineffective.
Because there is concern that resistance will emerge
against the current first-line drugs, such as the artemisi-
nin-based combination therapy, there is currently great
interest in discovering the next generation of anti-malarial
drugs.
Terpenes isolated from the roots of several plant families
have a broad range of biological activities, including anti-
microbial and anti-plasmodial activity [1,2]. It has been
shown that a number of terpenes and terpene derivatives
isolated from a variety of sources ranging from plants to
marine fungi kill P. falciparum parasites [3-6]. Synthetic
cis-terpenones, including the oxidized derivative of
hydroxy-cis terpenone (OHCT), are synthetic analogues of
natural terpene quinone methides that have a broad spec-
trum of biological activities [7].
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Synthesis of HCT and OHCT was described previously
[7,8]. It was previously shown that OHCT protects human
liver cells against aflatoxin and inhibits activity of liver
microsomal cytochrome P450 3A4 [9]. This enzyme not
only activates toxins, such as aflatoxin [10], but also con-
tributes to the degradation of anti-malarials, such as
artemisinin, thus suggesting that OHCT might increase
the half-life of current anti-malarials [11]. Based on the
anti-plasmodial effects of terpenes [1,2], the anti-malarial
effects of OHCT were investigated.
Methods
Culture of Plasmodium falciparum
Four clones of P. falciparum, the chloroquine-sensitive
clone HB3, the two chloroquine-resistant clones, FCR3-
Gambia and Dd2Nm-Indochina, and the laboratory-
induced artemisinin-resistant 7G6R, were cultured by a
method modified from that of Trager and Jensen [12] in a
5% CO2 atmosphere at 37°C.
In vitro selection of artemisinin-resistant parasite lines
The Plasmodium falciparum 7G8 clone was used for the
selection of artemisinin (ART) resistance. Drug resistance
selection experiments were performed as previously
described [13]. After the parasitaemia reached 2–3%, fro-
zen stocks of ART-selected parasites were prepared with
Glycerolyte.
Anti-malarial in vitro activity
Chloroquine diphosphate, artemisinin (Sigma Aldrich),
and OHCT were dissolved in medium (RPMI 1640), eth-
anol and DMSO, respectively. Compounds were further
diluted in medium to give a final concentration of 0.1%
ethanol or DMSO. Solutions were checked to determine
that precipitation did not occur under these conditions.
Parasite growth was estimated by microscopic observation
of Giemsa-stained blood smears and the parasite lactate
dehydrogenase (pLDH) activity [14]. Effective concentra-
tions that prevented survival of parasites were determined.
Unless indicated, all results presented are the means of at
least three independent experiments, and each experi-
ment was performed in duplicate. Assays were performed
for 48 h at concentrations ranging from 25 nM-50 μM.
Production of Plasmodium falciparum gametocytes
The P. falciparum Dd2Nm clone was cultured in medium
supplemented with 0.5% Albumax II, and O+ human
erythrocytes. The culture was treated with PIGPA solution
(50 mM hydrogen phosphate and 5 mM adenine in 0.9%
(w/v) NaCl, pH7.2 and 50 mg/L of hypoxanthine) as pre-
viously described [15]. Gametocytes were cultured in 2%
erythrocyte suspension and started with 1% parasitaemia,
containing mostly ring stage trophozoite after synchroni-
zation with sorbitol treatment. The medium was replaced
on days 4, 6 and 8. After sorbitol treatments on day 9, 10
and 11, the number of asexual parasites was reduced to
99%. For sorbitol treatment, 2.5 volumes of 5% (w/v)
sorbitol were added once a day. Pure gametocyte cultures
of P. falciparum Dd2Nm clone were achieved on day 11
with an average number of gametocytes of 315 and 282
per 8,500 erythrocytes. These gametocytes that were used
in the drug studies were in the range of 19% stage I, 21%
stage II, 39% stage III and 21% stage IV.
Gametocytocidal effects of OHCT against P. falciparum 
in vitro
Following sorbitol treatment, an aliquot of 150 μL of a
2.0% erythrocyte suspension containing gametocytes was
transferred to a 96-well plate containing 5 μL of drugs in
each well at a concentration ranging from 50 μM-25 nM
for another 48 h. Thin blood films were prepared and
gametocytes were counted per 7,000–10,000 erythrocytes.
The effect of each drug concentration was assessed in two
independent experiments in duplicate. The gametocyto-
cidal action of each drug was recorded and the IC50 and
IC90 were determined.
Time of OHCT action on the erythrocytic life cycle
Plasmodium falciparum cultures were synchronized with
5% sorbitol and the Percoll-Sorbitol method. Dilutions of
Table 2: Time course of OHCT action.
Time (min) Parasitaemia (%)
30 min 8.6
60 8.5
120 8.6
240 8.1
360 6
480 4.7
Vehicle (0.1% DMSO) 8.9
Media 9.1
The P. falciparum clone Dd2 (CQR) was treated with 0.5 μM OHCT 
for the times shown. Parasite viability was measured by the lactate 
dehydrogenase assay.
Table 1: Inhibition of Plasmodium survival by OHCT (nM)*
Dd2Nm HB3 FCR3 78GR
OHCT-IC50 85 ± 36.1 38 ± 9.7 93 ± 48.7 3.9 ± 0.5
-IC90 422 ± 27.4 523 ± 310 407 ± 150 17.4 ± 0.9
Chlor-IC50 85 ± 22.5 181 ± 92.8
-IC90 546 ± 69.1 < 20 524 ± 150.3
Artem-IC50 - - - 4.2 ± 0.4
-IC90 - - - 18.1 ± 1.0
* P. falciparum clones, two chloroquine resistant clones, Dd2Nm and 
FCR3, one chloroquine sensitive clone, HB3, and the artemisinin 
resistant clone 78 GR were incubated with five concentrations of 
OHCT for 48 h. Percent parasitaemia in 9,500 infected human 
erythrocytes was estimated by microscopic observation of Giemsa-
stained blood smears and by measurement of p(LDH). IC50 and IC90 
values (nM) represent the mean ± SE of 3 experiments (vehicle and 5 
duplicate concentrations per experiment).Malaria Journal 2009, 8:139 http://www.malariajournal.com/content/8/1/139
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OHCT, chloroquine, and artemisinin were prepared. After
synchronization, the parasites were plated at the ring stage
in 96-well plates. Cultures were treated with OHCT or
vehicle for 8 hours, and parasite viability was measured by
the parasite lactate dehydrogenase (pLDH) activity [14].
The cultures were centrifuged at 10,000 g (Fisher scien-
tific), washed in incomplete media and replaced with
fresh drug every hour to remove dead parasites.
Results
Anti-malarial activity of OHCT
The inhibitory concentration of OHCT was determined by
incubating the four P. falciparum clones with OHCT, chlo-
roquine and artemisinin, respectively. As shown in Table
1, OHCT inhibited survival of all P. falciparum clones
examined with an IC50 ranging from 3.9 – 93 nM, and its
IC90 was 17 – 523 nM. OHCT and chloroquine exhibited
similar potency against clone Dd2Nm. Although OHCT
had a lower IC50 than chloroquine against the chloro-
quine-resistant clone FCR3, it was less potent than chloro-
quine against the chloroquine-sensitive clone HB3.
Despite selection of 7G8R parasites that could survive in
artemisinin, the resistant parasites that were thawed and
cultured for the drug assay were consistently killed by
artemisinin at low nanomolar concentrations. It should
be noted that induced resistance to artemisinin in this
clone is reported to be unstable [13]. OHCT at low
nanomolar concentrations also inhibited survival of the
artemisinin resistant 7G8R clone. Thus, OHCT is effective
against all P. falciparum clones examined and might work
well in combination with established anti-malarials, such
as artemisinin and chloroquine.
OHCT at 1 – 16 μM kills most parasites within 24 hours
(data not shown). The time course of action of 1 μM
OHCT was investigated with the P. falciparum clone Dd2.
As shown in Table 2, the parasitaemia level decreased by
50% following treatment with OHCT for 8 h, suggesting
OHCT has a fast mechanism of action.
The P. falciparum clone, Dd2Nm, produces gametocytes in
culture. When OHCT was tested against gametocyte cul-
tures of P. falciparum Dd2Nm, decreased survival with an
IC50 17-fold lower than the IC50 of chloroquine with stage
I and stage II gametocytes and 26-fold lower than that of
chloroquine with stage III and IV gametocytes was
observed (Table 3 and Figure 1). The IC90  of OHCT
actions on gametocytes was 9-fold lower than that of chlo-
roquine (Table 3). These data indicate that P. falciparum
gametocytes are more sensitive to the action of OHCT
than chloroquine.
Effect of OHCT on developmental stages of P. falciparum gametocytes Figure 1
Effect of OHCT on developmental stages of P. falciparum gametocytes. Stage III gametocytes are resistant to chloro-
quine (A) whereas they are sensitive to OHCT (B). Gametocytes and dead parasites are shown by arrow. Representative 
Giemsa stain of P. falciparum (Dd2Nm) culture treated with chloroquine (A) and OHCT (B) at 0.5 μM for 48 h (1000×).
Table 3: OHCT (nM) inhibits growth of P. falciparum gametocytes*
OHCT
(Stage I and II)
Chloroquine
(Stage I and II)
OHCT
(Stage III and IV)
Chloroquine
(Stage III and IV)
(IC50) 22 ± 3.4 394 ± 127.0 36 ± 9.0 944 ± 92.0
(IC90) 174 ± 5.4 1520 ± 27.5 226 ± 49.3 2109 ± 85.2
*IC50 and IC90 values (nM) represent the mean ± SE of duplicate experiments, each performed in duplicate (vehicle and 8 concentrations per 
experimentMalaria Journal 2009, 8:139 http://www.malariajournal.com/content/8/1/139
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Discussion
In this paper, the in vitro anti-malarial activity of OHCT on
all blood stages of chloroquine-resistant and artemisinin-
resistant  P. falciparum clones, including the mosquito-
transmissible gametocytes, is reported. OHCT displayed a
significant inhibitory activity with an IC50 in the range of
3.9 – 93 nM depending on the parasite clone tested.
OHCT is very active against the gametocyte stages of P. fal-
ciparum. Unlike chloroquine OHCT killed stage III game-
tocytes [16]. OHCT, like artemisinin, rapidly kills the
early ring stage in vitro, suggesting that it could be used in
combination with a slow-acting drug, such as chloro-
quine. The previous demonstrations that OHCT inhibits
human liver cytochrome P450 3A4 [8,9] further suggests
that it may reduce metabolism of anti-malarial com-
pounds, such as artemisinin, that are metabolized by this
enzyme [11], thus increasing the half-life and rendering
them more effective. The inhibition of human liver cyto-
chrome P450 3A4 by OHCT was shown to be mixed com-
petitive inhibition indicating that OHCT was binding at a
site different from the active site [9]. Mixed enzymatic
inhibition takes place by alteration in the conformation of
cytochrome P450 3A4. Thus, OHCT would not be metab-
olized by cytochrome P450 3A4.
OHCT is a small hydrophobic organic molecule that does
not resemble any structure of known anti-malarials. In
addition, OHCT and its precursor exhibit no cytotoxicity
at concentrations of 10–60 μM in either human liver cells
[8,9] or human lung cells (unpublished data). Both com-
pounds are able to protect human liver cells against afla-
toxin B1-induced toxicity [7-9]. Therefore, it is conceivable
that the nanomolar anti-malarial activity of OHCT may
due to a unique mechanism yet to be identified, which is
currently under investigation. It is also conceivable that in
combination with other known anti-malarials, OHCT
would be effective in vivo against the drug resistant forms
of the parasite.
Conclusion
This study indicates that OHCT displays strong anti-
malarial activity in the nanomolar range against P. falci-
parum. In addition, OHCT is particularly effective on the
gametocyte stage. Previous studies suggest OHCT has the
potential for inhibiting metabolism of drugs used in anti-
malarial combination therapies and at μM concentrations
exhibits no toxicity to human cells in culture.
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